



PROGRAMME OF THE 4th EDITION OF THE HEALTHTECH INNOVATION DAYS ON 13 & 14 OCTOBER 2022 IN PARIS

Flagship event of the European health innovation ecosystem organised with the support of sponsors committed to the health sector

Paris, France, 12 July 2022 - The HealthTech Innovation Days (HTID®) event, organised by the HealthTech For Care endowment fund on the 13 and 14 of October 2022, under the High Patronage of Mr Emmanuel Macron, President of the French Republic, provides a forum for promising European life sciences companies to accelerate their growth and bring their solutions to patients faster. The 4th edition will take place in Paris, at [The HealthTech Space](#), 16 place de la Bourse, 75002 Paris, and virtually (hybrid format).

This European event combines one-to-one meetings between innovative European healthcare companies, investors, industrial and pharmaceutical companies, as well as conferences and round tables led by international opinion leaders.

Find the full programme and speakers [here](#).

The programme of the round tables of this 4th edition* is built around six major themes:

Towards a Europe of Health

European nations share common goals in terms of improving quality of life and increasing life expectancy. This convergence must lead the European Union to develop a strategy to advance the “right of access to health for all” and to meet the challenges of financing and innovation, in order to build a Europe of health at the service of all EU citizens and patients. Two round tables will address these issues:

- Build tomorrow’s healthcare for all European citizens
- Prospective scenario of the health system in 2032 and perspective at European level

The new frontiers of health innovation

The increasingly revolutionary advances in biotechnology (genomics, mRNA, immunology, etc.) are just beginning to bear fruit, while digitalisation and the advent of artificial intelligence are giving a powerful boost to all scientific areas. Six round tables will provide an overview of those new frontiers:

- Age-related diseases
- Impact of mRNA application in innovative drugs with the support of adapted manufacturing settings
- Translational microbiome medicine to treat serious oncology and infectious diseases
- How does artificial intelligence (AI) strengthen the full healthcare value chain?
- Women's Health
- Impact of new regulations on AI in healthcare

**As of 12/07/2022, the programme is under construction for some round tables*

The ongoing challenge of financing health innovation

Healthcare companies need strong and constant financial support at each stage of their development, from the laboratory to market access. They rely on public funding and a network of investors specialised in life sciences, which must constantly adapt to an unstable environment. Four round tables will review the challenges of these accelerations:

- Financial tools impacting health innovation growth in Europe
- Covid “wake up call” on health innovation investments – Opportunities and turbulence
- Importance of R&D collaborations between players
- IPO testimonials and expectations

Putting the patient back into the heart of innovation

"Placing citizens at the centre, empowering them to control their data in order to benefit from better healthcare" is the ambition stated by the European Commission. Digitalisation and point-of-care technologies are opening the way to a true consideration of the patient, both in terms of therapy and diagnosis, from the design of solutions to real-life monitoring. Two round tables are dedicated to this revolution!

- Highlights of [HealthTech For Patients #2](#)
- In vitro diagnostics in Europe: at the heart of patient care

Mobilising human resources and talent

The current revolutions in the healthcare sector can be a major growth engine for Europe. But this growth will require people with the right skills. The war for skills is already underway between ecosystems and companies. It entails investments but also new modes of organisation and cooperation.

- Matching the required talents for a sustainable development: constraints and opportunities

Building a transatlantic bridge to a sustainable and globally impactful societal health economy

The EU has many assets to leverage its potential. But it must not get isolated. The construction of an effective North Atlantic bridge is essential to ensure close and permanent cooperation between laboratories, international companies, in the fields of academic and applied research, long-term innovation and industrial cooperation. A round table will be dedicated to this ambition:

- Social impact of an effective North Atlantic Bridge for long term innovation

The 4th edition of HTID benefits from the support of sponsors: [Amgen](#), [BNP Paribas](#), [Bpifrance](#), [Bristol Myers Squibb](#), [Cepton Strategies/ Vintura](#), [Dechert](#), [EIT Health](#), [Euronext](#), [Ferring](#), [Jeito Capital](#), [Icosa](#), [Invest Securities](#), [Ipsen](#), [Leem](#) (Les Entreprises du Médicament), [Life Sciences Acceleration Alliance](#), [McDermott Will & Emery](#), [Microsoft](#), [Rothschild&Co](#), [Sanofi](#), [Servier](#), [Sofinnova Partners](#) and [Alpha Blue Ocean](#), allowing to bring together all the experts around the themes addressed.

About HealthTech For Care

The HealthTech For Care endowment fund is designed to support and promote access to healthcare for all, and more specifically to new medical technologies and medicines. The missions of the endowment fund are organised around three main areas: to support the development of the entire healthcare ecosystem, to accelerate the development of innovative therapies and medicines, and to promote better access for patients to the healthcare system in France and Europe. The governance of

HealthTech For Care includes Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Marc Deschamps, Eric Falcand, Frédéric Girard, Marc Julien, Anaïs Le Corvec, Cédric Moreau, Christian Pierret and Christian Policard.

HealthTech For Care benefits from the support of its founder **France Biotech** and the network of French health clusters: **Atlanpole biotherapies, BioValley France, EuroBioMed, LyonBioPole, Medicen and the NSL clubster**. The endowment fund is also supported by many European players: **Asebio, BioAlps, BIO Deutschland, BioWin, CEBR, Federchimica Assobiotec, flanders.bio, Medvia, HollandBIO, IREFI, Swiss Biotech** and French: **Business France**.

<https://www.linkedin.com/company/healthtech-for-care/>

<https://htfc-eu.com>

About HealthTech Innovation Days

The HTID® event, initiated by France Biotech, provides a platform for promising European life sciences companies to accelerate their growth and bring innovation to patients. This European event gathers each year more than 800 participants including 300 global investors, 150 innovative European healthcare companies and about 15 pharmaceutical groups. The 4th edition will take place on October 13 and 14, 2022 under a hybrid format, combining in-person presentations, panels and one-on-one meetings in Paris with a virtual platform. It is organised by the HealthTech For Care endowment fund. The HealthTech Innovation Days are sponsored by international pharmaceutical companies, other health innovation companies, investors and many international opinion leaders.

<https://htfc-eu.com/htid/>

Press contacts

Press Relations

Margaux Puech
mpuech@ulyse-communication.com
+33(0)7 86 16 01 09

HTFC

Nathalie Donne
nathalie.donne@insead.eu
+33(0)6 67 67 44 97

Press Relations

Pierre-Louis Germain
plgermain@ulyse-communication.com
+33(0)6 64 79 97 51

HTFC

Solène Goupy
solene.goupy@htfc-eu.com
+33(0)6 38 03 80 19